{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI could not be estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"29.3","upperLimit":"NA","value":"51.4"},{"groupId":"OG001","lowerLimit":"13.2","upperLimit":"25.7","value":"20.0"},{"groupId":"OG002","lowerLimit":"7.1","upperLimit":"12.9","value":"10.1"},{"comment":"Median and 95% CI could not be estimable due to low number of participants with events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"119"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).","id":"OG000","title":"RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).","id":"OG001","title":"RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).","id":"OG002","title":"RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).","id":"OG003","title":"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"}],"paramType":"MEDIAN","populationDescription":"SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, \"Overall number of participants analyzed\" signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.","reportingStatus":"POSTED","timeFrame":"From randomization date to the date of death (up to 172 Months)","title":"Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}